NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis $0.83 +0.05 (+6.96%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$0.82 -0.01 (-1.67%) As of 10/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rani Therapeutics Stock (NASDAQ:RANI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rani Therapeutics alerts:Sign Up Key Stats Today's Range$0.78▼$0.8350-Day Range$0.75▼$0.9252-Week Range$0.45▼$3.87Volume953,924 shsAverage Volume545,420 shsMarket Capitalization$115.53 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Rani Therapeutics Holdings, Inc. is a biotechnology company developing oral delivery technologies for biologic medicines that are typically administered by injection. The company’s platform is designed to transport therapeutic molecules through the stomach and release them in the small intestine, where they can be absorbed into the bloodstream. Its primary technology, the RaniPill capsule, is a robotic oral delivery system intended to deliver biologics, peptides and other large-molecule therapies. The company is developing proprietary product candidates based on this platform, including programs aimed at conditions such as osteoporosis and other chronic diseases. Its pipeline has included RT-102, an oral formulation of parathyroid hormone-related therapy, as well as additional candidates involving peptide and antibody-based medicines. Rani Therapeutics was founded by entrepreneur and medical-device innovator Mir Imran and is headquartered in San Jose, California. The company’s activities have focused on research, development and clinical testing rather than broad commercial distribution, with its programs being evaluated through clinical and regulatory processes. Talat Imran has served as the company’s chief executive officer, while Mir Imran has remained associated with the company as its founder and chairman.AI Generated. May Contain Errors. Read More Rani Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreRANI MarketRank™: Rani Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 519th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingRani Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRani Therapeutics has a consensus price target of $8.75, representing about 955.7% upside from its current price of $0.83.Amount of Analyst CoverageRani Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Rani Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rani Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rani Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.97% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 14.96, which indicates bearish sentiment.Change versus previous monthShort interest in Rani Therapeutics has recently increased by 11.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentRani Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for RANI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership4.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Rani Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $50,040.00 in company stock, which represents 0.0433% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,040.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.73% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions30.19% of the stock of Rani Therapeutics is held by institutions.Read more about Rani Therapeutics' insider trading history. Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RANI Stock News HeadlinesRani Therapeutics Holdings, Inc. Announces Acceptance Of RaniPill Capsule Platform Technology Into U.S. Food And Drug Administration Emerging Technology ProgramOctober 6 at 2:41 PM | marketscreener.comMRani Therapeutics' RaniPill Accepted Into FDA Emerging Technology ProgramOctober 5 at 12:38 AM | rttnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)October 5 at 8:00 AM | globenewswire.comRani Therapeutics (NASDAQ:RANI) and Surrozen (NASDAQ:SRZN) Critical SurveySeptember 27, 2026 | americanbankingnews.comRani Therapeutics to Participate in Upcoming September ConferencesSeptember 8, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)August 25, 2026 | theglobeandmail.comCanaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)August 20, 2026 | theglobeandmail.comSee More Headlines RANI Stock Analysis - Frequently Asked Questions How have RANI shares performed this year? Rani Therapeutics' stock was trading at $1.35 at the beginning of the year. Since then, RANI shares have decreased by 38.6% and is now trading at $0.8288. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The company had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.93 million. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rani Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO). Company Calendar Last Earnings8/13/2026Today10/07/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RANI's financial health is in the Red zone, according to TradeSmith. RANI has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RANI CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees69Year Founded2012Price Target and Rating Average Price Target for Rani Therapeutics$8.75 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+955.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.67 million Net MarginsN/A Pretax Margin-685.34% Return on Equity-104.60% Return on Assets-65.17% Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.31 Sales & Book Value Annual Sales$4.88 million Price / Sales23.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book2.44Miscellaneous Outstanding Shares139,395,000Free Float102,135,000Market Cap$115.53 million OptionableOptionable Beta0.69 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RANI) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
